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Abstract
Background: A recent genome-wide association study has identified a new susceptibility locus, kinesin family member 1B
gene (KIF1B), strongly associated with progression from chronic hepatitis B (CHB) to hepatitis B virus-related hepatocellular
carcinoma (HCC) in Chinese population, this study was carried out to explore the role of the genetic variants in KIF1B in the
development of chronic hepatitis B.
Methodology/Principal Findings: Three KIF1B polymorphisms (rs8019, rs17401924, and rs17401966) were selected and
genotyped in 473 CHB patients and 580 controls with no history of CHB. Odds ratios (ORs) and 95% confidence intervals
(CIs) were calculated by logistic regression model. None of these three SNPs showed association with CHBs after adjusting
for age and gender. Equivalence-based method analysis confirmed the absence of association. In the further haplotype
analysis, three common haplotypes were observed in this study population, but no significant effect was also found for
haplotypes in the progression to CHB.
Conclusions/Significance: This study showed the new locus identified for HCC, KIF1B, was not associated with progression
to CHB, implying distinct genetic susceptibility factor contributes to the progression from hepatitis B virus infection to HCC.
Nevertheless, further comprehensive analyses are warranted to dissect the mechanism.
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Introduction
H e p a t i t i sBv i r u s( H B V )i n f e c t ion is one of most challenging
global public health problems, with more than 2 billion people
infected [1,2]. Epidemiological studies have shown a regional
diversity of prevalence, with low rate (0.1–2.0%) in the USA and
western Europe and high rate (8.0–20.0%) in southeast Asia and
sub-Saharan regions [1]. While in China, a national survey in
2006 reported a 7.18% rate of HBsAg in the general population
aged 1–59 [3,4,5]. HBV infection leads to a wide spectrum of
outcomes. It has been estimated that 90–95% of individuals can
successfully clarify HBV, and only 5–10% would develop
chronic hepatitis B (CHB) [6]. Among those CHB individuals,
20–30% would develop liver cirrhosis and 5% further progress
to hepatocellular carcinoma (HCC) [7]. HCC is the third most
common cause of cancer-related death, and more than 80% of
HCC cases can be attributable to chronic infection with HBV in
hyper-endemic regions, suggesting CHB was a major risk factor
for development of HCC [8]. The enormous variation in clinical
outcome of HBV infection highlights the importance of
identification of mechanism underlying the progression of
HBV exposure to CHB for prevention against HBV-induced
fatal liver disease. Although the environmental factors such as
alcohol abuse, infection age, and co-infection with other
hepatitis virus unveiled as risk factors of HBV-induced liver
disease, genetic factors may also influence clinical progression
after HBV exposure, which is indicated by familial studies [9].
In fact, multiple candidate genes, such as IFNG, TNF, VDR,a n d
HLA loci, have been extensively investigated in the progression
to CHB, but results were inclusive [10–13]. A recent genome-
wide association study (GWAS) by Kamatani et al. in Japanese
population has suggested two SNPs of rs3077 and rs9277535 in
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infection of HBV [14]. Immediately, we successfully validated
these SNPs in two Chinese independently population [15].
However, these two variants could account for only a small
portion of CHB, and additional variants remains to be
identified.
Interestingly, a GWAS conducted in Chinese population by
Zhang H et al. raised a new susceptibility locus (rs17401966) in
kinesin family member 1B gene (KIF1B) at chromosome 1p36.22,
which was reported to be associated with HBV-related HCC in six
independent populations [16]. However, no comprehensive
analysis has been performed to explore this genetic variant on
the progression of CHB. Given the established relationship
between HBV infection and HCC, a hypothesis was therefore
raised naturally that this new identified loci was also involved on
the progression of CHB. To test this hypothesis, a case-control
study containing 473 CHB patients and 580 controls matched in
age and gender with no history of CHB, was conducted to explore
the associations between the progression to CHB and three
candidate SNPs in KIF1B, one SNP rs17401966 from GWAS




This study consisted of 473 CHB cases and 580 controls. All
subjects were unrelated Han Chinese from Beijing city and its
surrounding region. CHB patients were recruited from two
infectious diseases hospital, Beijing Ditan Hospital and Beijing
You’an Hospital between November 2001 and August 2004. The
diagnosis of CHB was conducted based on HBsAg seropositive,
anti-HBs seronegative, and continuously abnormal alanine
aminotransferase (ALT) and asparate aminotransferase (AST)
for more than six months. Controls matched in age and gender
were selected from a physical examination in Peking Union
Medical College Hospital in 2004, who had no medical history of
chronic hepatitis B and HBV vaccination. Subjects who were
positive for HBsAg were excluded from the controls. At
recruitment, written informed consent was obtained from each
subject and personal information from each participant regard-
ing demographic characteristics such as gender, age, and history
of HBV vaccination were collected by questionnaire. This study
was approved by the institutional review boards of the Chinese
Academy of Medical Sciences Cancer Institute and Tongji
Medical College of Huazhong University of Science and
Technology.
Serological testing
Enzyme-linked immunoadsorbent assay (ELISA) was used to
detect the serum HBsAg, anti-HBs and anti-HBc (IMX; Abbott
Diagnostics, North Chicago, IL, USA).
Identification of Candidate SNPs
In addition to the SNP of rs17401966 identified by the GWAS
in Chinese population, two other candidate SNPs in the intron of
KIF1B gene were identified by bioinformatics analysis. The SNP
of rs8019, which may located in the binding site of micro-
RNA, was selected using an integrated bioinformatics tool
‘‘SNP Info’’(http://manticore.niehs.nih.gov/snpfunc.htm) [17].
And rs17401924 was predicted to influence the gene splicing, which
was analyzed by ‘‘ESE finder’’ (http://rulai.cshl.edu/cgi-bin/tools/
ESE3/esefinder.cgi?process=home) [18].
Polymorphism genotyping
Genomic DNA was extracted from peripheral blood lympho-
cytes. All subjects were genotyped using TaqMan real-time
polymerase chain reaction (Applied Biosystems, Foster City, CA)
without knowledge of subjects’ infection status. The program was
heating to 95uC for 10 minutes followed by 40 cycles of 95uC for
15 seconds and 60uC for 1 minute. The ABI Prism 7900HT
Sequence Detection System was used to read the reacted plates
and analyze the endpoint fluorescence. To ensure the accuracy of
genotyping, a 15% random sample was tested twice by different
investigators. The results were concordant for all of the duplicate
sets.
Statistical analysis and haplotype construction
The differences in distribution of genotype between CHB cases
and controls were tested by x
2 test. Logistic regression was used to
evaluate the associations between KIF1B genotypes or haplotypes
and the outcome of HBV infection. Odds ratios (ORs) and their
95% confidence intervals (CIs) were calculated after adjustment
for age and sex where appropriate. Nonsuperiority test was used to
confirm the absence of association between all SNPs detected and
progression to CHB [19]. All statistical analyses were conducted
by Statistical Analysis System Software (version 9.2; SAS Institute,
Cary NC). Linkage disequilibrium (LD) of the three SNPs was
estimated using Haploview [20]. Haplotypes were reconstructed
and Haplotype frequencies were analyzed using Phase 2.1 [21].
Results
Subjects characteristics
A total of 473 chronic HB patients (377 males and 96 females)
and 580 controls (462 males and 118 females) were enrolled in this
study, with mean age of 34.13613.56 years. Both age and gender
distribution was comparable between CHB and controls. The
baseline characteristic of CHB patients and controls were shown in
Table 1.
KIF1B SNPs genotypes and risk of CHB
The genotype distributions of KIF1B candidate SNPs are shown
in Table 2. The minor allelic frequencies (MAF) for the
rs17401966, rs8019 and rs17401924 variants were 0.26, 0.38,
and 0.27 in CHB patients and 0.28, 0.37, and 0.28 in controls,
respectively. No significant differences were found in the genotype
frequencies between CHB patients and controls. Also, no
significant association was observed between the rs17401966 AG
(OR=1.01; 95% CI, 0.79–1.31) or GG genotype (OR=0.70;
95% CI, 0.43–1.14) and progression to CHB after adjusting for
age and gender using logistic regression analysis (table 2).
Similarly, the other two SNPs, rs8019 and rs17401924, also
Table 1. Distributions of select characteristics among CHB
patients and controls.
Variable Controls (%) CHB patients (%) P value
Total 580 473
Age at enrollment, years 34.43613.75 33.75613.34 0.415
Gender
Male 462 (79.7) 377 (79.7) 0.984
Female 118 (20.3) 96(20.3)
doi:10.1371/journal.pone.0028839.t001
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(table 2).
Haplotypes and risk of CHB
We further performed haplotypes analysis of these three SNPs
(in the order of rs8019, rs17401924, and rs17401966, data is
showed in Table 3). LD analysis showed that these three SNPs
were in strong linkage disequilibrium, with a D9 of 0.972
(r
2=0.595) for rs8019 and rs17401924, 0.921 (r
2=0.524) for
rs8019 and rs17401966, and 0.931 (r
2=0.853) for rs17401924 and
rs17401966 in our study population. Eight haplotypes were
observed in the present study, of which, only three haplotypes
AAA, CGG and CAA were the most prevalent haplotypes both in
CHB patients and controls owing to strong LD in these three
SNPs. Haplotype analysis found that individuals carrying the CAA
or CGG haplotype showed no increased risk of progression to
CHB with reference of the AAA haplotype. Meanwhile other five
haplotypes composing these three SNPs with frequencies smaller
than 5% would not be evaluated in the haplotype association
study.
Equivalence-based method to confirm the absence of
association between KIF1b SNPs and risk of CHB
Nonsuperiority test was used to confirm the absence of
association of rs8019*C, rs17401966*G, and rs17401924*G with
the progression of CHB. The null hypothesis is that the frequency
of rs8019*C, rs17401966*G, and rs17401924*G in CHB patients
is greater by D compared to the frequency in controls. The
specified amount D was set by 5% because the lowest difference of
rs17401966*G between CHB and HCC patients in five indepen-
dently populations in the GWAS data were 7.2%. So, a 5% excess
in cases can be regard as a stringent margin.
The corresponding nonsuperiority P-values for rs8019,
rs17401966 and rs17401924 was 0.002, 0.05 and 0.017,
respectively, which support the absence of association between
these three SNPs and development of CHB.
Discussion
In the study, we conducted a case-control study to firstly
investigate whether a new genetic susceptibility locus associated
with HBV-related HCC identified by GWAS, KIF1B, was
involved in development of CHB. However, none of the three
candidate SNPs (rs8019, rs17401924, and rs17401966) in KIF1B
was significantly associated with the progression to CHB, and
equivalence-based test confirmed the absence of association.
Since CHB has been verified to be closely associated with HCC,
identification of the genetic predictors of CHB development is very
important for fighting against HBV-related HCC. Although
researchers have paid much attention to identify genetic
susceptibility loci to CHB during past decades, the specific genetic
alteration underlying progression to CHB was far from clear.
Recently, a new susceptibility locus, KIF1B rs17401966 at 1p36.22
region, was identified to be involved in the progression from CHB
to HCC by a GWAS study in Chinese population [16], but the
effect of this SNP was unclear in the progression from HBV
exposure to CHB. In this study, we investigated this SNP and
other two predicted functional SNPs in KIFIB in 473 CHB cases
and 580 controls with no medical history of CHB, and no
significantly associations were observed between these three SNPs
and the progression to CHB after adjusting age and gender. The
results indicate that the genetic variants in KIF1B may only play
role in the progression from CHB to HCC, but not in the
progression to CHB. Similarly result was found by a recent GWAS
in Japanese that a identified genetic locus for hepatitis C virus-
related HCC was not associated with chronic hepatitis C
Table 2. KIF1B genotype frequencies and ORs for the





(n=473) OR (95% CI)
a P value
N( % ) N( % )
rs8019ARC
AA 232 (40.0) 177 (37.4) Reference
AC 265 (45.7) 230 (48.6) 1.14 (0.87–1.48) 0.339
CC 83 (14.3) 66 (14.0) 1.04 (0.72–1.52) 0.835
AC+CC 348 (60.0) 296 (62.6) 1.11 (0.87–1.43) 0.396
rs17401966ARG
AA 305 (52.6) 254 (53.7) Reference
AG 225 (38.8) 190 (40.2) 1.01 (0.79–1.31) 0.915
GG 50 (8.6) 29 (6.1) 0.70 (0.43–1.14) 0.152
AG+GG 275 (47.4) 219 (46.3) 0.96 (0.75–1.22) 0.723
rs17401924ARG
AA 307 (52.9) 249 (52.6) Reference
AG 222 (38.3) 192 (40.6) 1.07 (0.83–1.38) 0.625
GG 51 (8.8) 32 (6.8) 0.78 (0.48–1.24) 0.290
AG+GG 273 (47.1) 224 (47.4) 1.01 (0.79–1.29) 0.928
aData were calculated by unconditional logistic regression, adjusted for sex and
age.
doi:10.1371/journal.pone.0028839.t002







n=473 OR (95% CI)
a P value
No. of chromosomes (%) No. of chromosomes (%)
AAA 720 (62.1) 565 (59.7) Reference
CAA 107 (9.2) 106 (11.2) 1.26 (0.94–1.69) 0.115
CGG 312 (26.9) 227 (24.0) 0.93 (0.76–1.14) 0.466
aData were calculated by unconditional logistic regression, adjusted for sex and age.
bThe haplotypes were in the order of rs8019, rs17401924, and rs17401966, and haplotypes with frequencies ,5% were not shown in the table.
doi:10.1371/journal.pone.0028839.t003
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contribute to corresponding step of HCV-induced HCC develop-
ment . The genome-wide analyses on loss of heterozygosity (LOH)
in HCC by Li et al. further support our current result, which
suggested the LOH of 1p36.21–36.32 region was significant
related to HCC development, but not associated with the
progression to CHB [23]. Noteworthy, the new identified KIF1B
locus for HCC is located at 1p36 region, which encodes two
spliced isoforms of kinesin protein (KIF1Ba and KIF1Bb) involved
in the transport of organelles and vesicles [24]. Of these two
isoforms, KIF1Bb has been elucidated to act as a tumor suppressor
in multiple cancers by acting a variety of inhibitors of cell
proliferation and/or activators of apoptotic cell death [25,26].
Moreover, because a non-significant difference test cannot be
interpreted as acceptance of the null hypothesis, equivalence-based
method that provide the probability of observing a lack of
association by chance was conducted to avoid the false-negative
results in this study. P-values of nonsuperiority test for rs8019,
rs17401966 and rs17401924 is 0.002, 0.050 and 0.017, respec-
tively, and the nonexistence of association between KIF1B and
CHB progression is confirmed. Taken together, our current result,
plus these published evidence, outlined a hypothetical theory that
variable genetic susceptibility mechanisms underlie different
procedural steps from HBV infection to hepatocarcinogenesis,
and strongly indicated that the genetic variants in KIF1B
significantly contributed to the progression of CHB to HCC, but
not the CHB susceptibility.
In conclusion, this current study highlights the specificity of the
KIF1B genetic variants for the progression from CHB to HCC,
and the genetic susceptibility mechanism underlying the progres-
sion to CHB emergently needs further comprehensive analyses to
elucidate.
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